IDH has been proven as a reliable prognostic marker by several studies, but a two-gene predictor study by Molenaar et al. correlates with progression-free survival linked to the genetic and epigenetic status of IDH1 and/or MGMT in both primary and secondary glioblastomas [46,47]. This evidence concerns the gene IDH2 and glioblastoma.